BASSI, SIMONA
 Distribuzione geografica
Continente #
NA - Nord America 536
EU - Europa 362
AS - Asia 263
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.193
Nazione #
US - Stati Uniti d'America 536
VN - Vietnam 146
GB - Regno Unito 97
SE - Svezia 75
CN - Cina 55
DE - Germania 49
IT - Italia 36
SG - Singapore 30
UA - Ucraina 18
IN - India 15
RU - Federazione Russa 14
CH - Svizzera 13
FR - Francia 12
IE - Irlanda 11
TG - Togo 11
CI - Costa d'Avorio 9
FI - Finlandia 9
BE - Belgio 8
EE - Estonia 7
BG - Bulgaria 6
JO - Giordania 6
ZA - Sudafrica 6
TR - Turchia 4
NG - Nigeria 3
RO - Romania 3
HK - Hong Kong 2
IR - Iran 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
GR - Grecia 1
HR - Croazia 1
JP - Giappone 1
LB - Libano 1
NL - Olanda 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.193
Città #
Dong Ket 86
Southend 85
Chandler 65
Fairfield 59
Ashburn 58
Ann Arbor 53
Houston 42
Woodbridge 35
Seattle 30
Singapore 27
Wilmington 24
Princeton 14
Boardman 13
Bern 12
Jacksonville 12
Dublin 11
Lomé 11
Cambridge 10
Turin 10
Abidjan 9
Helsinki 9
Brussels 8
Santa Clara 8
Berlin 7
Nanjing 7
Padova 7
Westminster 7
Amman 6
Falls Church 6
Sofia 6
Bremen 5
Guangzhou 5
Beijing 4
Florence 4
Abeokuta 3
Changsha 3
Jinan 3
Milan 3
Saint Petersburg 3
San Diego 3
Verona 3
Dearborn 2
Haikou 2
Hebei 2
Istanbul 2
Kuban 2
Lanzhou 2
Mersin 2
Mountain View 2
Munich 2
Mülheim 2
New York 2
Tappahannock 2
Tianjin 2
Washington 2
Ardabil 1
Bratislava 1
Carol Stream 1
Chongqing 1
Cupertino 1
Den Haag 1
Des Moines 1
Dongguan 1
Foshan 1
Frankfurt am Main 1
Handan 1
Hangzhou 1
Harbin 1
Henderson 1
Hunedoara 1
Hyderabad 1
Jiaxing 1
Langfang 1
Los Angeles 1
Mahé 1
Nanchang 1
Ningbo 1
Norwalk 1
Pitesti 1
Riyadh 1
Saint Quentin 1
San Mateo 1
Shenyang 1
Shenzhen 1
Stockholm 1
Taizhou 1
Tokyo 1
Wuhan 1
Xiamen 1
Yubileyny 1
Zanjan 1
Zhengzhou 1
Zhoukou 1
Totale 842
Nome #
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 221
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 220
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 176
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 173
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 150
null 102
null 79
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 55
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. 39
Totale 1.215
Categoria #
all - tutte 2.622
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.622


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020121 0 0 0 0 0 0 0 39 34 21 12 15
2020/2021203 28 11 4 9 4 8 1 5 19 9 8 97
2021/2022239 68 4 14 23 18 11 4 10 9 15 35 28
2022/2023259 28 43 17 32 17 21 7 14 34 7 21 18
2023/202461 2 9 5 11 4 14 2 6 0 2 5 1
2024/202594 3 22 6 13 25 14 11 0 0 0 0 0
Totale 1.215